<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00549757</url>
  </required_header>
  <id_info>
    <org_study_id>CSPP100E2337</org_study_id>
    <secondary_id>2007-000860-25</secondary_id>
    <nct_id>NCT00549757</nct_id>
  </id_info>
  <brief_title>Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases)</brief_title>
  <acronym>ALTITUDE</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Determine Whether, in Patients With Type 2 Diabetes at High Risk for Cardiovascular and Renal Events, Aliskiren, on Top of Conventional Treatment, Reduces Cardiovascular and Renal Morbidity and Mortality</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine whether, in patients with type 2 diabetes and
      pre-existing disease of the heart and the circulatory system and/or the kidney, aliskiren at
      a target dose of 300 mg once daily (compared to placebo), on top of conventional treatment,
      reduces death and disease caused by the heart, the circulatory system and the kidney.

      AMENDMENT 4 RATIONALE (MARCH 2012) :

      Protocol amendment 4 served to address the data monitoring committee recommendation dated 14
      Dec 2011 to discontinue study treatment in all participating patients. It also addressed the
      subsequent Health Authorities request to implement a 12 month safety follow-up period (actual
      duration was 9 months in average) post study drug discontinuation.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of benefit and safety concern
  </why_stopped>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Occurrence of Primary Composite Endpoint (Core : Active Treatment Phase)</measure>
    <time_frame>Time from randomization to the first event (Maximum 50 months)</time_frame>
    <description>Occurrence was defined as the first event of the following composite primary endpoint:
Cardiovascular (CV) death
Resuscitated sudden death
Non-fatal myocardial infarction (MI)
Non-fatal stroke
Unplanned hospitalization for heart failure (HF)
Onset of end-stage renal disease (ESRD) or death due to renal failure. Onset of ESRD was defined as initiation of dialysis, renal transplantation, or a serum creatinine concentration above 6.0 mg/dL (530 μmol/L), sustained for at least a month.
Doubling of baseline serum creatinine concentration, sustained for at least one month. To fulfill the endpoint, the serum creatinine concentration had to be above the upper limit of normal for men and women according to the central laboratory. The upper limit of normal for men is 1.20 mg/dL and for women is 0.91 mg/dL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Cardiovascular (CV) Death (Core: Active Treatment Phase)</measure>
    <time_frame>Time from randomization to the first event (Maximum 50 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Resuscitated Sudden Death (Core: Active Treatment Phase)</measure>
    <time_frame>Time from randomization to the first event (Maximum 50 Months)</time_frame>
    <description>Resuscitated sudden death was adjudicated when a subject experiences sudden death or cardiac arrest and is successfully resuscitated by cardioversion, defibrillation or cardiopulmonary resuscitation with a meaningful recovery of consciousness. This definition excludes known transient losses of consciousness such as seizure or vasovagal episodes that do not reflect significant cardiac dysfunction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Fatal/Non-fatal Myocardial Infarction (MI) (Core: Active Treatment Phase)</measure>
    <time_frame>Time from randomization to the first event (Maximum 50 Months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Fatal/Non-fatal Stroke (Core: Active Treatment Phase)</measure>
    <time_frame>Time from randomization to the first event (Maximum 50 Months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Onset of End-stage Renal Disease (ESRD) (Core: Active Treatment Phase)</measure>
    <time_frame>Time from randomization to the first event (Maximum 50 Months)</time_frame>
    <description>ESRD is defined as initiation of dialysis, renal transplantation, or a serum creatinine concentration above 6.0 mg/dL (530 µmol per liter) or renal death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Doubling of Baseline Serum Creatinine Concentration, Sustained for at Least One Month (Core: Active Treatment Phase)</measure>
    <time_frame>Time from randomization to the first event (Maximum 50 Months)</time_frame>
    <description>To fulfill the endpoint, the serum creatinine concentration had to be above the upper limit of normal for men and women according to the central laboratory. The upper limit of normal for men is 1.20 mg/dL and for women is 0.91 mg/dL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Unplanned Hospitalization for Heart Failure (Core: Active Treatment Phase)</measure>
    <time_frame>Time from randomization to the first event (Maximum 50 Months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With All Cause Mortality (Core: Active Treatment Phase)</measure>
    <time_frame>Time from randomization to the first event (Maximum 50 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Occurrence of Primary Composite Endpoint (Extension Phase)</measure>
    <time_frame>From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)</time_frame>
    <description>Occurrence was defined as the first event of the following composite primary endpoint:
Cardiovascular (CV) death
Resuscitated sudden death
Non-fatal myocardial infarction (MI)
Non-fatal stroke
Unplanned hospitalization for heart failure (HF)
Onset of end-stage renal disease (ESRD) or death due to renal failure. Onset of ESRD was defined as initiation of dialysis, renal transplantation, or a serum creatinine concentration above 6.0 mg/dL (530 μmol/L), sustained for at least a month.
Doubling of baseline serum creatinine concentration, sustained for at least one month. To fulfill the endpoint, the serum creatinine concentration had to be above the upper limit of normal for men and women according to the central laboratory. The upper limit of normal for men is 1.20 mg/dL and for women is 0.91 mg/dL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Cardiovascular (CV) Death (Extension Phase)</measure>
    <time_frame>from cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Resuscitated Sudden Death (Extension Phase)</measure>
    <time_frame>From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Fatal/Non-fatal Myocardial Infarction (MI) (Extension Phase)</measure>
    <time_frame>From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 month in average)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Fatal/Non-fatal Stroke (Extension Phase)</measure>
    <time_frame>From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Onset of End-stage Renal Disease (ESRD) (Extension Phase)</measure>
    <time_frame>From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)</time_frame>
    <description>ESRD is defined as initiation of dialysis, renal transplantation, or a serum creatinine concentration above 6.0 mg/dL (530 µmol per liter) or renal death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Doubling of Baseline Serum Creatinine Concentration, Sustained for at Least One Month (Extension Phase)</measure>
    <time_frame>From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)</time_frame>
    <description>To fulfill the endpoint, the serum creatinine concentration had to be above the upper limit of normal for men and women according to the central laboratory. The upper limit of normal for men is 1.20 mg/dL and for women is 0.91 mg/dL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Unplanned Hospitalization for Heart Failure (Extension Phase)</measure>
    <time_frame>From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With All Cause Mortality (Extension Phase)</measure>
    <time_frame>from cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Occurrence of Secondary Cardiovascular Composite Endpoint (Core: Active Treatment Phase)</measure>
    <time_frame>Time from randomization to the first event (Maximum 50 months)</time_frame>
    <description>Occurrence was defined as the first event of the following secondary cardiovascular composite endpoint:
Cardiovascular (CV) death
Resuscitated sudden death
Non-fatal myocardial infarction (MI)
Non-fatal stroke
Unplanned hospitalization for heart failure (HF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Occurrence of Secondary Renal Composite Endpoint (Core: Active Treatment Phase)</measure>
    <time_frame>Time from randomization to the first event (Maximum 50 months)</time_frame>
    <description>Occurrence was defined as the first event of the following secondary renal composite endpoint:
Onset of end-stage renal disease (ESRD) or death due to renal failure. Onset of ESRD was defined as initiation of dialysis, renal transplantation, or a serum creatinine concentration above 6.0 mg/dL (530 μmol/L), sustained for at least a month.
Doubling of baseline serum creatinine concentration, sustained for at least one month. To fulfill the endpoint, the serum creatinine concentration had to be above the upper limit of normal for men and women according to the central laboratory.The upper limit of normal for men is 1.20 mg/dL and for women is 0.91 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Occurrence of Secondary Cardiovascular Composite Endpoint (Extension Phase)</measure>
    <time_frame>From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)</time_frame>
    <description>Occurrence was defined as the first event of the following secondary cardiovascular composite endpoint:
Cardiovascular (CV) death
Resuscitated sudden death
Non-fatal myocardial infarction (MI)
Non-fatal stroke
Unplanned hospitalization for heart failure (HF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Occurrence of Secondary Renal Composite Endpoint (Extension Phase)</measure>
    <time_frame>From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)</time_frame>
    <description>Occurrence was defined as the first event of the following secondary renal composite endpoint:
Onset of end-stage renal disease (ESRD) or death due to renal failure. Onset of ESRD was defined as initiation of dialysis, renal transplantation, or a serum creatinine concentration above 6.0 mg/dL (530 μmol/L), sustained for at least a month.
Doubling of baseline serum creatinine concentration, sustained for at least one month. To fulfill the endpoint, the serum creatinine concentration had to be above the upper limit of normal for men and women according to the central laboratory. The upper limit of normal for men is 1.20 mg/dL and for women is 0.91 mg/dL.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Participants With Angioedema/Angioedema-like or Colorectal Events (Core : Active Treatment Phase)</measure>
    <time_frame>Time from randomization to the first event (Maximum 50 months)</time_frame>
    <description>AEs of special interest were reported according to a post-marketing commitment to Health Authorities and included angioedema/angioedema-like events and colorectal events/ procedures</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) to Month 6 and to Last Measurement (Core : Active Treatment Phase)</measure>
    <time_frame>Baseline, Month 6 , last measurement (maximum at 50 months)</time_frame>
    <description>Baseline is the geometric mean of last 3 measurements before visit 3, Post-baseline value is the geometric mean of last 3 measurements during each visit.
Change from Baseline = Post - Baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Changes in Estimated Glomerular Filtration Rate (eGFR) From Baseline to Month 3 and Month 6 (Core : Active Treatment Phase)</measure>
    <time_frame>Baseline to Month 3 and Month 6</time_frame>
    <description>The eGFR calculation was based on the Abbreviated Modification of Diet in Renal Disease (MDRD) Study Equation. Using this method, the applicable MDRD formula to calculate eGFR was as follows:
Estimated GFR (mL/min/1.73 m^2) = 175 x (serum creatinine in mg/dL) -1.154 x (Age in years) -0.203 x (0.742 if female) x (1.210 if Black)
Mean changes in eGFR from baseline to month 3 and month 6 were included for analysis. The LS Mean and Standard Error were based on an ANCOVA repeated-measure model with treatment, visit, treatment-by-visit and baseline eGFR as effect terms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants With Angioedema/Angioedema-like Events or Colorectal Events (Extension Phase)</measure>
    <time_frame>From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)</time_frame>
    <description>AEs of special interest were reported according to a post-marketing commitment to Health Authorities and included angioedema/angioedema-like events and colorectal events/ procedures.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8606</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Aliskiren</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Core (Double Blind) phase, Aliskiren 150 mg once daily (o.d.) for 4 weeks; then patient was uptitrated to 300 mg o.d. at Visit 5/Week 4 (or 150 mg o.d. if patient could not tolerate target dose of study drug). Visits took place at 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.
With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In Core (Double Blind) phase, placebo to match aliskiren 150 mg once daily (o.d.) for 4 weeks; from Visit 5/Week 4 placebo to match aliskiren 300 mg o.d. (or placebo to match aliskiren 150 mg if patient could not tolerate target dose of study drug). Visits took place 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.
With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <description>Aliskiren 150 mg film-coated tablets</description>
    <arm_group_label>Aliskiren</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match aliskiren 150 mg film-coated tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes and at least one of the following:

               -  Macroalbuminuria and an eGFR ≥30 mL/min/1.73 m2

               -  Microalbuminuria and a reduced kidney function (eGFR eGFR ≥30 and &lt;60 mL/min/1.73
                  m2)

               -  A history of CV disease (previous MI, previous stroke, heart failure, coronary
                  artery disease, history of percutaneous coronary intervention, angiography proven
                  stenosis ≥50% in at least one coronary artery and a reduced kidney function (eGFR
                  ≥30 and &lt;60 mL/min/1.73 m2)

          -  Concomitant treatment should follow national guidelines and must include either an
             Angiotensin-converting-enzyme-inhibitor (ACEi) or an Angiotensin-receptor-blocker
             (ARB) but not both.

        Exclusion Criteria:

          -  Type 1 diabetes mellitus

          -  Cardiovascular event or procedure ≤ 3 months prior to Visit 1

          -  Unstable serum creatinine

          -  Hypertension: Mean sitting systolic blood pressure (msSBP) ≥ 135 and &lt; 170 mmHg or
             Mean sitting diastolic blood pressure (msDBP) ≥ 85 and &lt; 110 mmHg unless treated with
             at least 3 anti-hypertensive medications

          -  Hypertension msSBP ≥ 170 or msDBP ≥ 110 mmHg

          -  Baseline Serum Potassium &gt; 5.0 mmol/L

          -  Patients who are treated with two renin-angiotensin-aldosterone-system-blockers

          -  Patients with NYHA class III or IV heart failure

          -  Known renal artery stenosis

          -  Previous randomization into the AVOID trial (CSPP100C2201)

        EXCLUSION SPECIFIC TO THE SAFETY FOLLOW-UP PERIOD:

        - Aliskiren or aliskiren containing fixed combination products must not be used

        Other protocol-defined inclusion/exclusion criteria applied
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muscle Shoals</city>
        <state>Alabama</state>
        <zip>35662</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Burlingame</city>
        <state>California</state>
        <zip>94010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978-1522</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <zip>06610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <zip>33311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <zip>33313</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cumming</city>
        <state>Georgia</state>
        <zip>30041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Champaign</city>
        <state>Illinois</state>
        <zip>61820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lake Zurich</city>
        <state>Illinois</state>
        <zip>60047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Slidell</city>
        <state>Louisiana</state>
        <zip>70458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Haverhill</city>
        <state>Massachusetts</state>
        <zip>01830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jamaica Plain</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Natick</city>
        <state>Massachusetts</state>
        <zip>01760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <zip>48154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Belzoni</city>
        <state>Mississippi</state>
        <zip>39038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gulfport</city>
        <state>Mississippi</state>
        <zip>39501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110-1093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fremont</city>
        <state>Nebraska</state>
        <zip>68025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dover</city>
        <state>New Hampshire</state>
        <zip>03820-2403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Princeton Junction</city>
        <state>New Jersey</state>
        <zip>08550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lyndhurst</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lansdale</city>
        <state>Pennsylvania</state>
        <zip>19446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Melrose Park</city>
        <state>Pennsylvania</state>
        <zip>19027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aiken</city>
        <state>South Carolina</state>
        <zip>29801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Collierville</city>
        <state>Tennessee</state>
        <zip>38017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>North Richland Hills</city>
        <state>Texas</state>
        <zip>76180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-4801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508-0002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bennington</city>
        <state>Vermont</state>
        <zip>05201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22304-2315</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Burke</city>
        <state>Virginia</state>
        <zip>22015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Appleton</city>
        <state>Wisconsin</state>
        <zip>54911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>1428</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1280AEB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1408INH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1416DRJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1425AST</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Florida</city>
        <state>Buenos Aires</state>
        <zip>B1602BPD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lanus</city>
        <state>Buenos Aires</state>
        <zip>B8000XAV</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ramos Mejia</city>
        <state>Buenos Aires</state>
        <zip>B1704ETD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zarate</city>
        <state>Buenos Aires</state>
        <zip>2800</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000AII</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000CXH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000DFD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2001ODA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S200CVD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos aires</city>
        <zip>C1120AAC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1405BCH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000AAW</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000EVQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000FGG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000IUG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000JHQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5009BSN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5016KEH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Corrientes</city>
        <zip>W3400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Fe</city>
        <zip>S3000FNF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Fe</city>
        <zip>S3000FSO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Fe</city>
        <zip>S3000FVA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bregenz</city>
        <zip>A-6900</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Feldkirch</city>
        <zip>6807</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Innsbruck</city>
        <zip>INNSBRUCK</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vienna</city>
        <zip>1030</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>A-1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>A-1220</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brussel</city>
        <zip>9100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>De Pinte</city>
        <zip>9840</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Louvière</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ronse</city>
        <zip>9600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seraing</city>
        <zip>4100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sint-Gillis-Waas</city>
        <zip>9170</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Turnhout</city>
        <zip>2300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vilvoorde</city>
        <zip>1800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Willebroek</city>
        <zip>2830</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salvador</city>
        <state>BA</state>
        <zip>40050-410</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fortaleza</city>
        <state>CE</state>
        <zip>60120-021</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fortaleza</city>
        <state>CE</state>
        <zip>60430-370</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vitoria</city>
        <state>ES</state>
        <zip>29040-091</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Juiz de Fora</city>
        <state>MG</state>
        <zip>36036-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Belem</city>
        <state>PA</state>
        <zip>66073-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20020-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20551-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90020-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13060-904</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13083-190</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marilia</city>
        <state>SP</state>
        <zip>17519-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santos</city>
        <state>SP</state>
        <zip>11045-904</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Jose do Rio Preto</city>
        <state>SP</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sorocaba</city>
        <state>SP</state>
        <zip>18030-210</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>04023-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5J 3N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5N 3Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6E 1M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2V 4W3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 3P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bay Roberts</city>
        <state>Newfoundland and Labrador</state>
        <zip>A0A 1G0</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1E 4J8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6Z 4N5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7M 4Y1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 6V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Courtice</city>
        <state>Ontario</state>
        <zip>L1E 3C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Etobicoke</city>
        <state>Ontario</state>
        <zip>M9R 4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B 2H3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6H 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1J 2K1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 7W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1H 3G4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thornhill</city>
        <state>Ontario</state>
        <zip>L4J 8L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 2T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>N6G 4X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mirabel</city>
        <state>Quebec</state>
        <zip>J7J 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <zip>H9R 4S3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1G 3Y8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1W 4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1G 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ste-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trois-Rivières</city>
        <state>Quebec</state>
        <zip>G8Z 3R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7H 5M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ouest-Montreal</city>
        <zip>H2W1R7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100083</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510180</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050051</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150086</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Changsha City</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650101</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100028</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100088</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100176</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chengdu</city>
        <zip>610072</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chongqing</city>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guangzhou</city>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200233</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tianjin</city>
        <zip>300142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Florida Blanca</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Medellín</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brno-Bohunice</city>
        <zip>639 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brno</city>
        <zip>61300</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ceske Budejovice</city>
        <zip>370 87</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ostrava</city>
        <zip>702 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pardubice</city>
        <zip>53002</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pisek</city>
        <zip>397 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prague 2</city>
        <zip>128 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prague 2</city>
        <zip>128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prague 4 - Krc</city>
        <zip>14059</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prague 5 - Motol</city>
        <zip>15112</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aalborg</city>
        <zip>DK-9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Copenhagen NV</city>
        <zip>DK-2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frederiksberg</city>
        <zip>DK-2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gentofte</city>
        <zip>DK-2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hillerød</city>
        <zip>DK-3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roskilde</city>
        <zip>DK-4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Slagelse</city>
        <zip>DK-4200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Svendborg</city>
        <zip>DK-5700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Århus</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00250</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hyvinkää</city>
        <zip>FIN-05850</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kajaani</city>
        <zip>FIN-87140</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kuopio</city>
        <zip>FIN-70211</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lohja</city>
        <zip>FIN-08200</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oulu</city>
        <zip>90100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>OYS</city>
        <zip>FIN-90029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pori</city>
        <zip>28120</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tammisaari</city>
        <zip>10600</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valkeakoski</city>
        <zip>37600</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Besancon Cedex</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bondy</city>
        <zip>93143</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Corbeil Essonnes</city>
        <zip>91100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Rochelle</city>
        <zip>17019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lagny sur Marne</city>
        <zip>77405</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Limoges Cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lyon Cedex 03</city>
        <zip>69394</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris cedex 18</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris Cedex 4</city>
        <zip>75181</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poitiers Cedex</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63741</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Asslar</city>
        <zip>35614</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barsinghausen</city>
        <zip>30890</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bensheim</city>
        <zip>64625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13597</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>14193</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bottrop</city>
        <zip>46242</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bremen</city>
        <zip>28277</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bretten</city>
        <zip>75015</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cloppenburg</city>
        <zip>49661</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dippoldiswalde</city>
        <zip>01744</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40210</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45134</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45138</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fuldatal</city>
        <zip>34233</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hagen</city>
        <zip>58095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22393</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heilbronn</city>
        <zip>74072</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heilbronn</city>
        <zip>74076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ingelheim</city>
        <zip>55218</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kassel</city>
        <zip>34117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krefeld</city>
        <zip>47798</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Messkirch</city>
        <zip>88605</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muehldorf am Inn</city>
        <zip>84453</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Neuwied</city>
        <zip>56564</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Offenbach</city>
        <zip>63065</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rehburg-Loccum</city>
        <zip>31547</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riesa</city>
        <zip>01587</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Schauenburg-Elgershausen</city>
        <zip>34270</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Schwabenheim</city>
        <zip>55270</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Ingbert - Oberwuerzbach</city>
        <zip>66386</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ursensollen</city>
        <zip>92289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wetter</city>
        <zip>58300</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wiehl</city>
        <zip>51674</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65183</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97072</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alexandroupolis</city>
        <zip>GR 68 100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens - GR</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>GR 115 21</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>GR 115 22</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>GR 115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>GR 11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ioannina</city>
        <zip>GR 45500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Patras</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Piraeurs</city>
        <zip>GR 184 54</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57001</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>GR 546 39</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guatemala City</city>
        <zip>01001</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guatemala City</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guatemala City</city>
        <zip>01011</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guatemala City</city>
        <zip>01015</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baja</city>
        <zip>6500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Balatonfured</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1115</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>H-1032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4004</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gyula</city>
        <zip>5703</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaposvar</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pecs</city>
        <zip>7324</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh, INDIA</state>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500018</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Banglaore</city>
        <state>Karnataka</state>
        <zip>560038</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mangalore</city>
        <state>Karnataka</state>
        <zip>575001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kochi</city>
        <state>Kerala</state>
        <zip>682 026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411030</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vellore</city>
        <state>Tamil Nadu</state>
        <zip>632004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangalore</city>
        <zip>560 034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chennai</city>
        <zip>600010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chennai</city>
        <zip>600086</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hyderabad</city>
        <zip>500 063</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kolkota</city>
        <zip>700020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Delhi</city>
        <zip>110 029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>L'Aquila</city>
        <state>AQ</state>
        <zip>67100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Belluno</city>
        <state>BL</state>
        <zip>32100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Campobasso</city>
        <state>CB</state>
        <zip>86100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caserta</city>
        <state>CE</state>
        <zip>81100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chieti</city>
        <state>CH</state>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cuneo</city>
        <state>CN</state>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cosenza</city>
        <state>CS</state>
        <zip>87100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Catanzaro</city>
        <state>CZ</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cona</city>
        <state>FE</state>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Foggia</city>
        <state>FG</state>
        <zip>71100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Arenzano</city>
        <state>GE</state>
        <zip>16011</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pozzilli</city>
        <state>IS</state>
        <zip>86077</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lecco</city>
        <state>LC</state>
        <zip>23900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Passirana di Rho</city>
        <state>MI</state>
        <zip>20017</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Perugia</city>
        <state>PG</state>
        <zip>06100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pordenone</city>
        <state>PN</state>
        <zip>33170</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parma</city>
        <state>PR</state>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Casorate Primo</city>
        <state>PV</state>
        <zip>27022</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stradella</city>
        <state>PV</state>
        <zip>27049</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ravenna</city>
        <state>RA</state>
        <zip>48100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00163</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00186</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cava De' Tirreni</city>
        <state>SA</state>
        <zip>84013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mercato San Severino</city>
        <state>SA</state>
        <zip>84085</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salerno</city>
        <state>SA</state>
        <zip>84125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Siena</city>
        <state>SI</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Olbia</city>
        <state>SS</state>
        <zip>07026</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sassari</city>
        <state>SS</state>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10154</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vittorio Veneto</city>
        <state>TV</state>
        <zip>31029</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Daniele Del Friuli</city>
        <state>UD</state>
        <zip>33038</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Udine</city>
        <state>UD</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Venezia</city>
        <state>VE</state>
        <zip>30174</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Isernia</city>
        <zip>86170</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>451-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>455-8530</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>462-0802</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>462-0825</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Asahi</city>
        <state>Chiba</state>
        <zip>289-2511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kasuga</city>
        <state>Fukuoka</state>
        <zip>816-0864</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>800-0296</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koriyama-city</city>
        <state>Fukushima</state>
        <zip>963-8851</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido</state>
        <zip>078-8211</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo-city</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>003-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toride-city</city>
        <state>Ibaraki</state>
        <zip>302-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Takamatsu</city>
        <state>Kagawa</state>
        <zip>7600076</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aira-city</city>
        <state>Kagoshima</state>
        <zip>899-5431</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Isehara-city</city>
        <state>Kanagawa</state>
        <zip>259-1131</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <zip>210-0852</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yatsushiro</city>
        <state>Kumamoto</state>
        <zip>866-8660</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyoto-city</city>
        <state>Kyoto</state>
        <zip>612-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyoto-city</city>
        <state>Kyoto</state>
        <zip>615-0035</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sendai-city</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suwa</city>
        <state>Nagano</state>
        <zip>392-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Okayama-city</city>
        <state>Okayama</state>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Takatsuki-city</city>
        <state>Osaka</state>
        <zip>569-1096</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toyonaka</city>
        <state>Osaka</state>
        <zip>561-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yao-city</city>
        <state>Osaka</state>
        <zip>581-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tokorozawa</city>
        <state>Saitama</state>
        <zip>351-1151</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ohtsu-city</city>
        <state>Shiga</state>
        <zip>520-2192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shimizu</city>
        <state>Shizuoka</state>
        <zip>411-8611</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>103-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Takaoka</city>
        <state>Toyama</state>
        <zip>933-0955</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oita</city>
        <zip>870-0039</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oita</city>
        <zip>870-0192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Okayama</city>
        <zip>701-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ansan</city>
        <state>Gyeonggi-do</state>
        <zip>425-801</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Anyang</city>
        <state>Gyeonggi-do</state>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>110 744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bundang</city>
        <state>Seongnam</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Daejeon</city>
        <zip>301-747</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Incheon</city>
        <zip>400-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pusan</city>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>136 705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taegu</city>
        <zip>700 - 721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaunas</city>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Klaipeda</city>
        <zip>92304</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alkmaar</city>
        <zip>1851 JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Almelo</city>
        <zip>7609 PP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amersfoort</city>
        <zip>3800 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1061 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Apeldoorn</city>
        <zip>7334 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Arnhem</city>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Delft</city>
        <zip>2625 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Den Helder</city>
        <zip>1782 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Deventer</city>
        <zip>7416 SE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Doetinchem</city>
        <zip>7009 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dordrecht</city>
        <zip>3318AT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Eindhoven</city>
        <zip>5631 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goes</city>
        <zip>4462 RA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heerlen</city>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hoogeveen</city>
        <zip>7909 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hoogwoud</city>
        <zip>1718 BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Losser</city>
        <zip>7581 BV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Meppel</city>
        <zip>7943 KA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oude Pekela</city>
        <zip>9665 AR</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3045 PM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3083 AN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tiel</city>
        <zip>4002 WP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Venlo</city>
        <zip>5912 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Woerden</city>
        <zip>3443 GG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zwijndrecht</city>
        <zip>NL-3331 LZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zwolle</city>
        <zip>8025 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bergen</city>
        <zip>5013</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fredrikstad</city>
        <zip>1607</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Horten</city>
        <zip>3191</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hønefoss</city>
        <zip>3515</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oslo</city>
        <zip>0160</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Skedsmokorset</city>
        <zip>2020</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Skien</city>
        <zip>3722</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Spikkestad</city>
        <zip>3430</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stavanger</city>
        <zip>4011</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Svelvik</city>
        <zip>3060</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tromsø</city>
        <zip>NO-9038</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trondheim</city>
        <zip>NO-7011</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tønsberg</city>
        <zip>3103</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bellavista</city>
        <state>Lima</state>
        <zip>Callao 02</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cercado de Lima</city>
        <state>Lima</state>
        <zip>01</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Borja</city>
        <state>Lima</state>
        <zip>41</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Isidro</city>
        <state>Lima</state>
        <zip>27</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Martin de Porres</city>
        <state>Lima</state>
        <zip>31</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago de Surco</city>
        <state>Lima</state>
        <zip>33</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Almada</city>
        <zip>2801-951</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amadora</city>
        <zip>2720-276</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Linda-a-Velha</city>
        <zip>2799-523</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1169-024</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1250-203</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1495-005</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Matosinhos</city>
        <zip>4454-509</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Portimão</city>
        <zip>8500-388</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Maria da Feira</city>
        <zip>4520-211</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santarém</city>
        <zip>2000-153</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ponce</city>
        <zip>00733-1471</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>159964</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>168752</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <state>Slovak Republic</state>
        <zip>826 06</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <state>Slovak Republic</state>
        <zip>040 22</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zilina</city>
        <state>Slovak Republic</state>
        <zip>010 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Banksa Bystrica</city>
        <zip>SK 97 517</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>811 08</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>812 72</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>81369</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>833 48</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>851 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <zip>040 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lubochna</city>
        <zip>SK 03491</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lucenec</city>
        <zip>98439</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Martin</city>
        <zip>03601</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nitra</city>
        <zip>949 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Piestany</city>
        <zip>921 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prievidza</city>
        <zip>971 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trstena</city>
        <zip>549 16</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Somerset West</city>
        <state>Western Cape</state>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Durban</city>
        <zip>4030</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Durban</city>
        <zip>4052</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Durban</city>
        <zip>4110</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gauteng</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Johannesburg</city>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Port Elizabeth</city>
        <zip>6001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pretoria</city>
        <zip>0002</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cadiz</city>
        <state>Andalucia</state>
        <zip>11010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Granada</city>
        <state>Andalucia</state>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jerez de La Frontera</city>
        <state>Andalucia</state>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29018</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Málaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Puerto de Santa Maria</city>
        <state>Andalucia</state>
        <zip>11500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sanlúcar de Barrameda</city>
        <state>Andalucia</state>
        <zip>11540</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alcazar de San Juan</city>
        <state>Castilla la Mancha</state>
        <zip>13600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aranda de Duero</city>
        <state>Castilla y Leon</state>
        <zip>09400</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miranda de Ebro</city>
        <state>Castilla y Leon</state>
        <zip>09200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08905</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Girona</city>
        <state>Cataluña</state>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Pobla Llarga</city>
        <state>Cataluña</state>
        <zip>46670</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Llança</city>
        <state>Cataluña</state>
        <zip>17490</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manresa</city>
        <state>Cataluña</state>
        <zip>08240</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mollet del Vallés</city>
        <state>Cataluña</state>
        <zip>08100</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rubi</city>
        <state>Cataluña</state>
        <zip>08191</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Coloma de Gramanet</city>
        <state>Cataluña</state>
        <zip>08923</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tarrega</city>
        <state>Cataluña</state>
        <zip>25300</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vic</city>
        <state>Cataluña</state>
        <zip>08500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alacuas</city>
        <state>Comunidad Valenciana</state>
        <zip>46970</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alicante</city>
        <state>Comunidad Valenciana</state>
        <zip>03004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alzira</city>
        <state>Comunidad Valenciana</state>
        <zip>46600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Benidorm</city>
        <state>Comunidad Valenciana</state>
        <zip>03550</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Puerto de Sagunto</city>
        <state>Comunidad Valenciana</state>
        <zip>46520</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quart de Poblet</city>
        <state>Comunidad Valenciana</state>
        <zip>46930</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46019</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Xixona</city>
        <state>Comunidad Valenciana</state>
        <zip>03100</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mérida</city>
        <state>Extremadura</state>
        <zip>06800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Begonte</city>
        <state>Galicia</state>
        <zip>27373</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ferrol</city>
        <state>Galicia</state>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Coruña</city>
        <state>Galicia</state>
        <zip>15010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pontevedra</city>
        <state>Galicia</state>
        <zip>36071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vigo</city>
        <state>Galicia</state>
        <zip>36200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Islas Baleares</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alcorcón</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Arganda del Rey</city>
        <state>Madrid</state>
        <zip>28500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Civdad Real</city>
        <state>Madrid</state>
        <zip>13002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Murcia</city>
        <state>Madrid</state>
        <zip>30007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plentzia</city>
        <state>Pais Vasco</state>
        <zip>48620</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Sebastian</city>
        <state>Pais Vasco</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villabona</city>
        <state>Pais Vasco</state>
        <zip>20150</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zumarraga</city>
        <state>Pais Vasco</state>
        <zip>20700</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alfaro</city>
        <state>Rioja</state>
        <zip>26540</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Logroño</city>
        <state>Rioja</state>
        <zip>26005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hospitalet de Llbregat</city>
        <zip>08902</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28770</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Göteborg</city>
        <zip>SE-412 55</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Helsingborg</city>
        <zip>251 87</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Karlstad</city>
        <zip>651 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malmö</city>
        <zip>21152</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rättvik</city>
        <zip>79530</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stenstorp</city>
        <zip>SE-521 60</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Varberg</city>
        <zip>s-432 81</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Estavayer-le-Lac</city>
        <state>CH</state>
        <zip>1470</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ascona</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bolligen</city>
        <zip>3065</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruderholz</city>
        <zip>4101</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fribourg</city>
        <zip>1700</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Chaux-de-Fonds</city>
        <zip>2300</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lugano</city>
        <zip>6903</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Renens</city>
        <zip>1020</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Schaffhausen</city>
        <zip>8200</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Winterthur</city>
        <zip>8400</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zuerich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yungkang</city>
        <state>Tainan</state>
        <zip>710</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Niaosong Township</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung County</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Altunizade</city>
        <zip>34662</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06590</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gaziantep</city>
        <zip>27070</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>High Wycombe</city>
        <state>Buckinghamshire</state>
        <zip>HP11 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Truro</city>
        <state>Cornwall</state>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paignton</city>
        <state>Devon</state>
        <zip>TQ4 5LA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cornwall</city>
        <state>England</state>
        <zip>PL23 1DT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Welwyn Garden City,</city>
        <state>Hertfordshire</state>
        <zip>AL7 4HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gravesend</city>
        <state>Kent</state>
        <zip>DA1 24JW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12 8TA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>East Horsley</city>
        <state>Surrey</state>
        <zip>KT24 6QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Crawley</city>
        <state>West Sussex</state>
        <zip>RH10 7DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bath</city>
        <zip>BA2 3HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cardiff</city>
        <zip>CF5 4AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G21 3UW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Irvine</city>
        <zip>KA12 0AY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lancashire</city>
        <zip>FY3 7EN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lancashire</city>
        <zip>FY4 3AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>NW10 7NS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Merseyside</city>
        <zip>L7 8PX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rugby</city>
        <zip>CV21 5 PX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vale of Glanmorgan</city>
        <zip>CF63 4AR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wrexham</city>
        <zip>LL13 7TD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caracas</city>
        <state>Distrito Capital</state>
        <zip>1010</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caracas</city>
        <state>Distrito Capital</state>
        <zip>1020</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caracas</city>
        <state>Distrito Capital</state>
        <zip>1040</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caracas</city>
        <state>Distrito Capital</state>
        <zip>1080-A</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caracas</city>
        <state>Distrito Capital</state>
        <zip>1100</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Puerto Ordaz</city>
        <state>Estado Bolívar</state>
        <zip>8050</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Estado Carabobo</state>
        <zip>2001</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caracas</city>
        <state>Estado Miranda</state>
        <zip>1060</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Peru</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
    <country>Venezuela</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2007</study_first_submitted>
  <study_first_submitted_qc>October 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2007</study_first_posted>
  <results_first_submitted>February 3, 2014</results_first_submitted>
  <results_first_submitted_qc>February 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 18, 2014</results_first_posted>
  <last_update_submitted>April 1, 2014</last_update_submitted>
  <last_update_submitted_qc>April 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>renal morbidity and mortality</keyword>
  <keyword>cardiovascular disease</keyword>
  <keyword>micro-albuminuria</keyword>
  <keyword>macro-albuminuria</keyword>
  <keyword>RAAS</keyword>
  <keyword>renin inhibitor</keyword>
  <keyword>Reduced estimated glomerular filtration rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Per data monitoring committee (DMC) recommendation all patients were required to permanently stop study medication by 06Jan2012. A follow-up period (actual duration, 9 months in average) post study drug discontinuation on 7590 patients was implemented upon request of Health Authority following the recommendation of DMC to cease study treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Aliskiren</title>
          <description>In Core (Double Blind) phase, Aliskiren 150 mg once daily (o.d.) for 4 weeks; then patient was uptitrated to 300 mg o.d. at Visit 5/Week 4 (or 150 mg o.d. if patient could not tolerate target dose of study drug). Visits took place at 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.
With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>In Core (Double Blind) phase, placebo to match aliskiren 150 mg once daily (o.d.) for 4 weeks; from Visit 5/Week 4 placebo to match aliskiren 300 mg o.d. (or placebo to match aliskiren 150 mg if patient could not tolerate target dose of study drug). Visits took place 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.
With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Active Treatment Phase: Max. 50 Months</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4296">&quot;Started&quot; indicates randomized patients.</participants>
                <participants group_id="P2" count="4310"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="4274"/>
                <participants group_id="P2" count="4287"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="4272"/>
                <participants group_id="P2" count="4285"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4296"/>
                <participants group_id="P2" count="4310"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="590"/>
                <participants group_id="P2" count="462"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal laboratory value(s)</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal test procedure result(s)</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="2857"/>
                <participants group_id="P2" count="3019"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="188"/>
                <participants group_id="P2" count="200"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient's request</title>
              <participants_list>
                <participants group_id="P1" count="353"/>
                <participants group_id="P2" count="380"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incorrect Entry</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing data</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Period (in Average 9 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3773">As explained in &quot;pre-assignment detail&quot;, follow up was made after drug discontinuation</participants>
                <participants group_id="P2" count="3817">As explained in &quot;pre-assignment detail&quot;, follow up was made after drug discontinuation</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3148"/>
                <participants group_id="P2" count="3182"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="625"/>
                <participants group_id="P2" count="635"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="143"/>
                <participants group_id="P2" count="136"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient's request</title>
              <participants_list>
                <participants group_id="P1" count="421"/>
                <participants group_id="P2" count="436"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set (FAS) : All patients randomized except mis-randomized patients who did not receive study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Aliskiren</title>
          <description>In Core (Double Blind) phase, Aliskiren 150 mg once daily (o.d.) for 4 weeks; then patient was uptitrated to 300 mg o.d. at Visit 5/Week 4 (or 150 mg o.d. if patient could not tolerate target dose of study drug). Visits took place at 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.
With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>In Core (Double Blind) phase, placebo to match aliskiren 150 mg once daily (o.d.) for 4 weeks; from Visit 5/Week 4 placebo to match aliskiren 300 mg o.d. (or placebo to match aliskiren 150 mg if patient could not tolerate target dose of study drug). Visits took place 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.
With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4274"/>
            <count group_id="B2" value="4287"/>
            <count group_id="B3" value="8561"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.6" spread="9.62"/>
                    <measurement group_id="B2" value="64.4" spread="9.87"/>
                    <measurement group_id="B3" value="64.5" spread="9.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1393"/>
                    <measurement group_id="B2" value="1342"/>
                    <measurement group_id="B3" value="2735"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2881"/>
                    <measurement group_id="B2" value="2945"/>
                    <measurement group_id="B3" value="5826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Occurrence of Primary Composite Endpoint (Core : Active Treatment Phase)</title>
        <description>Occurrence was defined as the first event of the following composite primary endpoint:
Cardiovascular (CV) death
Resuscitated sudden death
Non-fatal myocardial infarction (MI)
Non-fatal stroke
Unplanned hospitalization for heart failure (HF)
Onset of end-stage renal disease (ESRD) or death due to renal failure. Onset of ESRD was defined as initiation of dialysis, renal transplantation, or a serum creatinine concentration above 6.0 mg/dL (530 μmol/L), sustained for at least a month.
Doubling of baseline serum creatinine concentration, sustained for at least one month. To fulfill the endpoint, the serum creatinine concentration had to be above the upper limit of normal for men and women according to the central laboratory. The upper limit of normal for men is 1.20 mg/dL and for women is 0.91 mg/dL.</description>
        <time_frame>Time from randomization to the first event (Maximum 50 months)</time_frame>
        <population>Full Analysis Set (FAS) - All patients randomized except mis-randomized patients who did not receive study drug. Mis-randomized patients were defined as not qualified for randomization and were inadvertently randomized into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>In Core (Double Blind) phase, Aliskiren 150 mg once daily (o.d.) for 4 weeks; then patient was uptitrated to 300 mg o.d. at Visit 5/Week 4 (or 150 mg o.d. if patient could not tolerate target dose of study drug). Visits took place at 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>In Core (Double Blind) phase, placebo to match aliskiren 150 mg once daily (o.d.) for 4 weeks; from Visit 5/Week 4 placebo to match aliskiren 300 mg o.d. (or placebo to match aliskiren 150 mg if patient could not tolerate target dose of study drug). Visits took place 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Occurrence of Primary Composite Endpoint (Core : Active Treatment Phase)</title>
          <description>Occurrence was defined as the first event of the following composite primary endpoint:
Cardiovascular (CV) death
Resuscitated sudden death
Non-fatal myocardial infarction (MI)
Non-fatal stroke
Unplanned hospitalization for heart failure (HF)
Onset of end-stage renal disease (ESRD) or death due to renal failure. Onset of ESRD was defined as initiation of dialysis, renal transplantation, or a serum creatinine concentration above 6.0 mg/dL (530 μmol/L), sustained for at least a month.
Doubling of baseline serum creatinine concentration, sustained for at least one month. To fulfill the endpoint, the serum creatinine concentration had to be above the upper limit of normal for men and women according to the central laboratory. The upper limit of normal for men is 1.20 mg/dL and for women is 0.91 mg/dL.</description>
          <population>Full Analysis Set (FAS) - All patients randomized except mis-randomized patients who did not receive study drug. Mis-randomized patients were defined as not qualified for randomization and were inadvertently randomized into the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4274"/>
                <count group_id="O2" value="4287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6"/>
                    <measurement group_id="O2" value="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Cardiovascular (CV) Death (Core: Active Treatment Phase)</title>
        <time_frame>Time from randomization to the first event (Maximum 50 months)</time_frame>
        <population>Full Analysis Set (FAS) - All patients randomized except mis-randomized patients who did not receive study drug. Mis-randomized patients were defined as not qualified for randomization and were inadvertently randomized into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>In Core (Double Blind) phase, Aliskiren 150 mg once daily (o.d.) for 4 weeks; then patient was uptitrated to 300 mg o.d. at Visit 5/Week 4 (or 150 mg o.d. if patient could not tolerate target dose of study drug). Visits took place at 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>In Core (Double Blind) phase, placebo to match aliskiren 150 mg once daily (o.d.) for 4 weeks; from Visit 5/Week 4 placebo to match aliskiren 300 mg o.d. (or placebo to match aliskiren 150 mg if patient could not tolerate target dose of study drug). Visits took place 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Cardiovascular (CV) Death (Core: Active Treatment Phase)</title>
          <population>Full Analysis Set (FAS) - All patients randomized except mis-randomized patients who did not receive study drug. Mis-randomized patients were defined as not qualified for randomization and were inadvertently randomized into the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4274"/>
                <count group_id="O2" value="4287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Resuscitated Sudden Death (Core: Active Treatment Phase)</title>
        <description>Resuscitated sudden death was adjudicated when a subject experiences sudden death or cardiac arrest and is successfully resuscitated by cardioversion, defibrillation or cardiopulmonary resuscitation with a meaningful recovery of consciousness. This definition excludes known transient losses of consciousness such as seizure or vasovagal episodes that do not reflect significant cardiac dysfunction.</description>
        <time_frame>Time from randomization to the first event (Maximum 50 Months)</time_frame>
        <population>Full Analysis Set (FAS) - All patients randomized except mis-randomized patients who did not receive study drug. Mis-randomized patients were defined as not qualified for randomization and were inadvertently randomized into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>In Core (Double Blind) phase, Aliskiren 150 mg once daily (o.d.) for 4 weeks; then patient was uptitrated to 300 mg o.d. at Visit 5/Week 4 (or 150 mg o.d. if patient could not tolerate target dose of study drug). Visits took place at 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>In Core (Double Blind) phase, placebo to match aliskiren 150 mg once daily (o.d.) for 4 weeks; from Visit 5/Week 4 placebo to match aliskiren 300 mg o.d. (or placebo to match aliskiren 150 mg if patient could not tolerate target dose of study drug). Visits took place 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Resuscitated Sudden Death (Core: Active Treatment Phase)</title>
          <description>Resuscitated sudden death was adjudicated when a subject experiences sudden death or cardiac arrest and is successfully resuscitated by cardioversion, defibrillation or cardiopulmonary resuscitation with a meaningful recovery of consciousness. This definition excludes known transient losses of consciousness such as seizure or vasovagal episodes that do not reflect significant cardiac dysfunction.</description>
          <population>Full Analysis Set (FAS) - All patients randomized except mis-randomized patients who did not receive study drug. Mis-randomized patients were defined as not qualified for randomization and were inadvertently randomized into the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4274"/>
                <count group_id="O2" value="4287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Fatal/Non-fatal Myocardial Infarction (MI) (Core: Active Treatment Phase)</title>
        <time_frame>Time from randomization to the first event (Maximum 50 Months)</time_frame>
        <population>Full Analysis Set (FAS) - All patients randomized except mis-randomized patients who did not receive study drug. Mis-randomized patients were defined as not qualified for randomization and were inadvertently randomized into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>In Core (Double Blind) phase, Aliskiren 150 mg once daily (o.d.) for 4 weeks; then patient was uptitrated to 300 mg o.d. at Visit 5/Week 4 (or 150 mg o.d. if patient could not tolerate target dose of study drug). Visits took place at 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>In Core (Double Blind) phase, placebo to match aliskiren 150 mg once daily (o.d.) for 4 weeks; from Visit 5/Week 4 placebo to match aliskiren 300 mg o.d. (or placebo to match aliskiren 150 mg if patient could not tolerate target dose of study drug). Visits took place 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Fatal/Non-fatal Myocardial Infarction (MI) (Core: Active Treatment Phase)</title>
          <population>Full Analysis Set (FAS) - All patients randomized except mis-randomized patients who did not receive study drug. Mis-randomized patients were defined as not qualified for randomization and were inadvertently randomized into the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4274"/>
                <count group_id="O2" value="4287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Fatal/Non-fatal Stroke (Core: Active Treatment Phase)</title>
        <time_frame>Time from randomization to the first event (Maximum 50 Months)</time_frame>
        <population>Full Analysis Set (FAS) - All patients randomized except mis-randomized patients who did not receive study drug. Mis-randomized patients were defined as not qualified for randomization and were inadvertently randomized into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>In Core (Double Blind) phase, Aliskiren 150 mg once daily (o.d.) for 4 weeks; then patient was uptitrated to 300 mg o.d. at Visit 5/Week 4 (or 150 mg o.d. if patient could not tolerate target dose of study drug). Visits took place at 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>In Core (Double Blind) phase, placebo to match aliskiren 150 mg once daily (o.d.) for 4 weeks; from Visit 5/Week 4 placebo to match aliskiren 300 mg o.d. (or placebo to match aliskiren 150 mg if patient could not tolerate target dose of study drug). Visits took place 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Fatal/Non-fatal Stroke (Core: Active Treatment Phase)</title>
          <population>Full Analysis Set (FAS) - All patients randomized except mis-randomized patients who did not receive study drug. Mis-randomized patients were defined as not qualified for randomization and were inadvertently randomized into the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4274"/>
                <count group_id="O2" value="4287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Onset of End-stage Renal Disease (ESRD) (Core: Active Treatment Phase)</title>
        <description>ESRD is defined as initiation of dialysis, renal transplantation, or a serum creatinine concentration above 6.0 mg/dL (530 µmol per liter) or renal death</description>
        <time_frame>Time from randomization to the first event (Maximum 50 Months)</time_frame>
        <population>Full Analysis Set (FAS) - All patients randomized except mis-randomized patients who did not receive study drug. Mis-randomized patients were defined as not qualified for randomization and were inadvertently randomized into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>In Core (Double Blind) phase, Aliskiren 150 mg once daily (o.d.) for 4 weeks; then patient was uptitrated to 300 mg o.d. at Visit 5/Week 4 (or 150 mg o.d. if patient could not tolerate target dose of study drug). Visits took place at 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>In Core (Double Blind) phase, placebo to match aliskiren 150 mg once daily (o.d.) for 4 weeks; from Visit 5/Week 4 placebo to match aliskiren 300 mg o.d. (or placebo to match aliskiren 150 mg if patient could not tolerate target dose of study drug). Visits took place 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Onset of End-stage Renal Disease (ESRD) (Core: Active Treatment Phase)</title>
          <description>ESRD is defined as initiation of dialysis, renal transplantation, or a serum creatinine concentration above 6.0 mg/dL (530 µmol per liter) or renal death</description>
          <population>Full Analysis Set (FAS) - All patients randomized except mis-randomized patients who did not receive study drug. Mis-randomized patients were defined as not qualified for randomization and were inadvertently randomized into the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4274"/>
                <count group_id="O2" value="4287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7"/>
                    <measurement group_id="O2" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Occurrence of Secondary Cardiovascular Composite Endpoint (Core: Active Treatment Phase)</title>
        <description>Occurrence was defined as the first event of the following secondary cardiovascular composite endpoint:
Cardiovascular (CV) death
Resuscitated sudden death
Non-fatal myocardial infarction (MI)
Non-fatal stroke
Unplanned hospitalization for heart failure (HF)</description>
        <time_frame>Time from randomization to the first event (Maximum 50 months)</time_frame>
        <population>Full Analysis Set (FAS) - All patients randomized except mis-randomized patients who did not receive study drug. Mis-randomized patients were defined as not qualified for randomization and were inadvertently randomized into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>In Core (Double Blind) phase, Aliskiren 150 mg once daily (o.d.) for 4 weeks; then patient was uptitrated to 300 mg o.d. at Visit 5/Week 4 (or 150 mg o.d. if patient could not tolerate target dose of study drug). Visits took place at 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>In Core (Double Blind) phase, Placebo to match aliskiren 150 mg once daily (o.d.) for 4 weeks; from Visit 5/Week 4 placebo to match aliskiren 300 mg o.d. (or placebo to match aliskiren 150 mg if patient could not tolerate target dose of study drug). Visits took place 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Occurrence of Secondary Cardiovascular Composite Endpoint (Core: Active Treatment Phase)</title>
          <description>Occurrence was defined as the first event of the following secondary cardiovascular composite endpoint:
Cardiovascular (CV) death
Resuscitated sudden death
Non-fatal myocardial infarction (MI)
Non-fatal stroke
Unplanned hospitalization for heart failure (HF)</description>
          <population>Full Analysis Set (FAS) - All patients randomized except mis-randomized patients who did not receive study drug. Mis-randomized patients were defined as not qualified for randomization and were inadvertently randomized into the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4274"/>
                <count group_id="O2" value="4287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4"/>
                    <measurement group_id="O2" value="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Occurrence of Secondary Renal Composite Endpoint (Core: Active Treatment Phase)</title>
        <description>Occurrence was defined as the first event of the following secondary renal composite endpoint:
Onset of end-stage renal disease (ESRD) or death due to renal failure. Onset of ESRD was defined as initiation of dialysis, renal transplantation, or a serum creatinine concentration above 6.0 mg/dL (530 μmol/L), sustained for at least a month.
Doubling of baseline serum creatinine concentration, sustained for at least one month. To fulfill the endpoint, the serum creatinine concentration had to be above the upper limit of normal for men and women according to the central laboratory.The upper limit of normal for men is 1.20 mg/dL and for women is 0.91 mg/dL.</description>
        <time_frame>Time from randomization to the first event (Maximum 50 months)</time_frame>
        <population>Full Analysis Set (FAS) - All patients randomized except mis-randomized patients who did not receive study drug. Mis-randomized patients were defined as not qualified for randomization and were inadvertently randomized into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>In Core (Double Blind) phase, Aliskiren 150 mg once daily (o.d.) for 4 weeks; then patient was uptitrated to 300 mg o.d. at Visit 5/Week 4 (or 150 mg o.d. if patient could not tolerate target dose of study drug). Visits took place at 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>In Core (Double Blind) Phase, Placebo to match aliskiren 150 mg once daily (o.d.) for 4 weeks; from Visit 5/Week 4 placebo to match aliskiren 300 mg o.d. (or placebo to match aliskiren 150 mg if patient could not tolerate target dose of study drug). Visits took place 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Occurrence of Secondary Renal Composite Endpoint (Core: Active Treatment Phase)</title>
          <description>Occurrence was defined as the first event of the following secondary renal composite endpoint:
Onset of end-stage renal disease (ESRD) or death due to renal failure. Onset of ESRD was defined as initiation of dialysis, renal transplantation, or a serum creatinine concentration above 6.0 mg/dL (530 μmol/L), sustained for at least a month.
Doubling of baseline serum creatinine concentration, sustained for at least one month. To fulfill the endpoint, the serum creatinine concentration had to be above the upper limit of normal for men and women according to the central laboratory.The upper limit of normal for men is 1.20 mg/dL and for women is 0.91 mg/dL.</description>
          <population>Full Analysis Set (FAS) - All patients randomized except mis-randomized patients who did not receive study drug. Mis-randomized patients were defined as not qualified for randomization and were inadvertently randomized into the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4274"/>
                <count group_id="O2" value="4287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Occurrence of Secondary Cardiovascular Composite Endpoint (Extension Phase)</title>
        <description>Occurrence was defined as the first event of the following secondary cardiovascular composite endpoint:
Cardiovascular (CV) death
Resuscitated sudden death
Non-fatal myocardial infarction (MI)
Non-fatal stroke
Unplanned hospitalization for heart failure (HF)</description>
        <time_frame>From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)</time_frame>
        <population>Extension-phase Analysis Set (EAS) – All patients who had at least one scheduled or unscheduled visit or who died post cut-off date 20-Dec-2011/end of treatment (EOT).</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Occurrence of Secondary Cardiovascular Composite Endpoint (Extension Phase)</title>
          <description>Occurrence was defined as the first event of the following secondary cardiovascular composite endpoint:
Cardiovascular (CV) death
Resuscitated sudden death
Non-fatal myocardial infarction (MI)
Non-fatal stroke
Unplanned hospitalization for heart failure (HF)</description>
          <population>Extension-phase Analysis Set (EAS) – All patients who had at least one scheduled or unscheduled visit or who died post cut-off date 20-Dec-2011/end of treatment (EOT).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3773"/>
                <count group_id="O2" value="3817"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Occurrence of Secondary Renal Composite Endpoint (Extension Phase)</title>
        <description>Occurrence was defined as the first event of the following secondary renal composite endpoint:
Onset of end-stage renal disease (ESRD) or death due to renal failure. Onset of ESRD was defined as initiation of dialysis, renal transplantation, or a serum creatinine concentration above 6.0 mg/dL (530 μmol/L), sustained for at least a month.
Doubling of baseline serum creatinine concentration, sustained for at least one month. To fulfill the endpoint, the serum creatinine concentration had to be above the upper limit of normal for men and women according to the central laboratory. The upper limit of normal for men is 1.20 mg/dL and for women is 0.91 mg/dL.</description>
        <time_frame>From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)</time_frame>
        <population>Extension-phase Analysis Set (EAS) – All patients who had at least one scheduled or unscheduled visit or who died post cut-off date 20-Dec-2011/end of treatment (EOT).</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Occurrence of Secondary Renal Composite Endpoint (Extension Phase)</title>
          <description>Occurrence was defined as the first event of the following secondary renal composite endpoint:
Onset of end-stage renal disease (ESRD) or death due to renal failure. Onset of ESRD was defined as initiation of dialysis, renal transplantation, or a serum creatinine concentration above 6.0 mg/dL (530 μmol/L), sustained for at least a month.
Doubling of baseline serum creatinine concentration, sustained for at least one month. To fulfill the endpoint, the serum creatinine concentration had to be above the upper limit of normal for men and women according to the central laboratory. The upper limit of normal for men is 1.20 mg/dL and for women is 0.91 mg/dL.</description>
          <population>Extension-phase Analysis Set (EAS) – All patients who had at least one scheduled or unscheduled visit or who died post cut-off date 20-Dec-2011/end of treatment (EOT).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3773"/>
                <count group_id="O2" value="3817"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Doubling of Baseline Serum Creatinine Concentration, Sustained for at Least One Month (Core: Active Treatment Phase)</title>
        <description>To fulfill the endpoint, the serum creatinine concentration had to be above the upper limit of normal for men and women according to the central laboratory. The upper limit of normal for men is 1.20 mg/dL and for women is 0.91 mg/dL.</description>
        <time_frame>Time from randomization to the first event (Maximum 50 Months)</time_frame>
        <population>Full Analysis Set (FAS) - All patients randomized except mis-randomized patients who did not receive study drug. Mis-randomized patients were defined as not qualified for randomization and were inadvertently randomized into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>In Core (Double Blind) phase, Aliskiren 150 mg once daily (o.d.) for 4 weeks; then patient was uptitrated to 300 mg o.d. at Visit 5/Week 4 (or 150 mg o.d. if patient could not tolerate target dose of study drug). Visits took place at 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>In Core (Double Blind) phase, placebo to match aliskiren 150 mg once daily (o.d.) for 4 weeks; from Visit 5/Week 4 placebo to match aliskiren 300 mg o.d. (or placebo to match aliskiren 150 mg if patient could not tolerate target dose of study drug). Visits took place 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Doubling of Baseline Serum Creatinine Concentration, Sustained for at Least One Month (Core: Active Treatment Phase)</title>
          <description>To fulfill the endpoint, the serum creatinine concentration had to be above the upper limit of normal for men and women according to the central laboratory. The upper limit of normal for men is 1.20 mg/dL and for women is 0.91 mg/dL.</description>
          <population>Full Analysis Set (FAS) - All patients randomized except mis-randomized patients who did not receive study drug. Mis-randomized patients were defined as not qualified for randomization and were inadvertently randomized into the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4274"/>
                <count group_id="O2" value="4287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6"/>
                    <measurement group_id="O2" value="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Unplanned Hospitalization for Heart Failure (Core: Active Treatment Phase)</title>
        <time_frame>Time from randomization to the first event (Maximum 50 Months)</time_frame>
        <population>Full Analysis Set (FAS) - All patients randomized except mis-randomized patients who did not receive study drug. Mis-randomized patients were defined as not qualified for randomization and were inadvertently randomized into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>In Core (Double Blind) phase, Aliskiren 150 mg once daily (o.d.) for 4 weeks; then patient was uptitrated to 300 mg o.d. at Visit 5/Week 4 (or 150 mg o.d. if patient could not tolerate target dose of study drug). Visits took place at 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>In Core (Double Blind) phase, placebo to match aliskiren 150 mg once daily (o.d.) for 4 weeks; from Visit 5/Week 4 placebo to match aliskiren 300 mg o.d. (or placebo to match aliskiren 150 mg if patient could not tolerate target dose of study drug). Visits took place 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Unplanned Hospitalization for Heart Failure (Core: Active Treatment Phase)</title>
          <population>Full Analysis Set (FAS) - All patients randomized except mis-randomized patients who did not receive study drug. Mis-randomized patients were defined as not qualified for randomization and were inadvertently randomized into the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4274"/>
                <count group_id="O2" value="4287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With All Cause Mortality (Core: Active Treatment Phase)</title>
        <time_frame>Time from randomization to the first event (Maximum 50 months)</time_frame>
        <population>Full Analysis Set (FAS) - All patients randomized except mis-randomized patients who did not receive study drug. Mis-randomized patients were defined as not qualified for randomization and were inadvertently randomized into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>In Core (Double Blind) phase, Aliskiren 150 mg once daily (o.d.) for 4 weeks; then patient was uptitrated to 300 mg o.d. at Visit 5/Week 4 (or 150 mg o.d. if patient could not tolerate target dose of study drug). Visits took place at 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>In Core (Double Blind) Phase, Placebo to match aliskiren 150 mg once daily (o.d.) for 4 weeks; from Visit 5/Week 4 placebo to match aliskiren 300 mg o.d. (or placebo to match aliskiren 150 mg if patient could not tolerate target dose of study drug). Visits took place 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With All Cause Mortality (Core: Active Treatment Phase)</title>
          <population>Full Analysis Set (FAS) - All patients randomized except mis-randomized patients who did not receive study drug. Mis-randomized patients were defined as not qualified for randomization and were inadvertently randomized into the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4274"/>
                <count group_id="O2" value="4287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4"/>
                    <measurement group_id="O2" value="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Occurrence of Primary Composite Endpoint (Extension Phase)</title>
        <description>Occurrence was defined as the first event of the following composite primary endpoint:
Cardiovascular (CV) death
Resuscitated sudden death
Non-fatal myocardial infarction (MI)
Non-fatal stroke
Unplanned hospitalization for heart failure (HF)
Onset of end-stage renal disease (ESRD) or death due to renal failure. Onset of ESRD was defined as initiation of dialysis, renal transplantation, or a serum creatinine concentration above 6.0 mg/dL (530 μmol/L), sustained for at least a month.
Doubling of baseline serum creatinine concentration, sustained for at least one month. To fulfill the endpoint, the serum creatinine concentration had to be above the upper limit of normal for men and women according to the central laboratory. The upper limit of normal for men is 1.20 mg/dL and for women is 0.91 mg/dL.</description>
        <time_frame>From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)</time_frame>
        <population>Extension-phase Analysis Set (EAS) – All patients who had at least one scheduled or unscheduled visit or who died post cut-off date 20-Dec-2011/EOT.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Occurrence of Primary Composite Endpoint (Extension Phase)</title>
          <description>Occurrence was defined as the first event of the following composite primary endpoint:
Cardiovascular (CV) death
Resuscitated sudden death
Non-fatal myocardial infarction (MI)
Non-fatal stroke
Unplanned hospitalization for heart failure (HF)
Onset of end-stage renal disease (ESRD) or death due to renal failure. Onset of ESRD was defined as initiation of dialysis, renal transplantation, or a serum creatinine concentration above 6.0 mg/dL (530 μmol/L), sustained for at least a month.
Doubling of baseline serum creatinine concentration, sustained for at least one month. To fulfill the endpoint, the serum creatinine concentration had to be above the upper limit of normal for men and women according to the central laboratory. The upper limit of normal for men is 1.20 mg/dL and for women is 0.91 mg/dL.</description>
          <population>Extension-phase Analysis Set (EAS) – All patients who had at least one scheduled or unscheduled visit or who died post cut-off date 20-Dec-2011/EOT.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3773"/>
                <count group_id="O2" value="3817"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Cardiovascular (CV) Death (Extension Phase)</title>
        <time_frame>from cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)</time_frame>
        <population>Extension-phase Analysis Set (EAS) – All patients who had at least one scheduled or unscheduled visit or who died post cut-off date 20-Dec-2011/EOT.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Cardiovascular (CV) Death (Extension Phase)</title>
          <population>Extension-phase Analysis Set (EAS) – All patients who had at least one scheduled or unscheduled visit or who died post cut-off date 20-Dec-2011/EOT.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3773"/>
                <count group_id="O2" value="3817"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Resuscitated Sudden Death (Extension Phase)</title>
        <time_frame>From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)</time_frame>
        <population>Extension-phase Analysis Set (EAS) – All patients who had at least one scheduled or unscheduled visit or who died post cut-off date 20-Dec-2011/EOT.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Resuscitated Sudden Death (Extension Phase)</title>
          <population>Extension-phase Analysis Set (EAS) – All patients who had at least one scheduled or unscheduled visit or who died post cut-off date 20-Dec-2011/EOT.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3773"/>
                <count group_id="O2" value="3817"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Fatal/Non-fatal Myocardial Infarction (MI) (Extension Phase)</title>
        <time_frame>From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 month in average)</time_frame>
        <population>Extension-phase Analysis Set (EAS) – All patients who had at least one scheduled or unscheduled visit or who died post cut-off date 20-Dec-2011/EOT.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Fatal/Non-fatal Myocardial Infarction (MI) (Extension Phase)</title>
          <population>Extension-phase Analysis Set (EAS) – All patients who had at least one scheduled or unscheduled visit or who died post cut-off date 20-Dec-2011/EOT.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3773"/>
                <count group_id="O2" value="3817"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Fatal/Non-fatal Stroke (Extension Phase)</title>
        <time_frame>From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)</time_frame>
        <population>Extension-phase Analysis Set (EAS) – All patients who had at least one scheduled or unscheduled visit or who died post cut-off date 20-Dec-2011/EOT.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Fatal/Non-fatal Stroke (Extension Phase)</title>
          <population>Extension-phase Analysis Set (EAS) – All patients who had at least one scheduled or unscheduled visit or who died post cut-off date 20-Dec-2011/EOT.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3773"/>
                <count group_id="O2" value="3817"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Onset of End-stage Renal Disease (ESRD) (Extension Phase)</title>
        <description>ESRD is defined as initiation of dialysis, renal transplantation, or a serum creatinine concentration above 6.0 mg/dL (530 µmol per liter) or renal death</description>
        <time_frame>From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Onset of End-stage Renal Disease (ESRD) (Extension Phase)</title>
          <description>ESRD is defined as initiation of dialysis, renal transplantation, or a serum creatinine concentration above 6.0 mg/dL (530 µmol per liter) or renal death</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3773"/>
                <count group_id="O2" value="3817"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Doubling of Baseline Serum Creatinine Concentration, Sustained for at Least One Month (Extension Phase)</title>
        <description>To fulfill the endpoint, the serum creatinine concentration had to be above the upper limit of normal for men and women according to the central laboratory. The upper limit of normal for men is 1.20 mg/dL and for women is 0.91 mg/dL.</description>
        <time_frame>From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)</time_frame>
        <population>Extension-phase Analysis Set (EAS) – All patients who had at least one scheduled or unscheduled visit or who died post cut-off date 20-Dec-2011/EOT.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Doubling of Baseline Serum Creatinine Concentration, Sustained for at Least One Month (Extension Phase)</title>
          <description>To fulfill the endpoint, the serum creatinine concentration had to be above the upper limit of normal for men and women according to the central laboratory. The upper limit of normal for men is 1.20 mg/dL and for women is 0.91 mg/dL.</description>
          <population>Extension-phase Analysis Set (EAS) – All patients who had at least one scheduled or unscheduled visit or who died post cut-off date 20-Dec-2011/EOT.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3773"/>
                <count group_id="O2" value="3817"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Unplanned Hospitalization for Heart Failure (Extension Phase)</title>
        <time_frame>From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)</time_frame>
        <population>Extension-phase Analysis Set (EAS) – All patients who had at least one scheduled or unscheduled visit or who died post cut-off date 20-Dec-2011/EOT.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Unplanned Hospitalization for Heart Failure (Extension Phase)</title>
          <population>Extension-phase Analysis Set (EAS) – All patients who had at least one scheduled or unscheduled visit or who died post cut-off date 20-Dec-2011/EOT.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3773"/>
                <count group_id="O2" value="3817"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With All Cause Mortality (Extension Phase)</title>
        <time_frame>from cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)</time_frame>
        <population>Extension-phase Analysis Set (EAS) – All patients who had at least one scheduled or unscheduled visit or who died post cut-off date 20-Dec-2011/EOT.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With All Cause Mortality (Extension Phase)</title>
          <population>Extension-phase Analysis Set (EAS) – All patients who had at least one scheduled or unscheduled visit or who died post cut-off date 20-Dec-2011/EOT.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3773"/>
                <count group_id="O2" value="3817"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Angioedema/Angioedema-like or Colorectal Events (Core : Active Treatment Phase)</title>
        <description>AEs of special interest were reported according to a post-marketing commitment to Health Authorities and included angioedema/angioedema-like events and colorectal events/ procedures</description>
        <time_frame>Time from randomization to the first event (Maximum 50 months)</time_frame>
        <population>Safety Set (SAF) - All patients who received at least one dose of trial medication. Patients were analyzed according to the treatment they received.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>In Core (Double Blind) phase, Aliskiren 150 mg once daily (o.d.) for 4 weeks; then patient was uptitrated to 300 mg o.d. at Visit 5/Week 4 (or 150 mg o.d. if patient could not tolerate target dose of study drug). Visits took place at 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>In Core (Double Blind) Phase, Placebo to match aliskiren 150 mg once daily (o.d.) for 4 weeks; from Visit 5/Week 4 placebo to match aliskiren 300 mg o.d. (or placebo to match aliskiren 150 mg if patient could not tolerate target dose of study drug). Visits took place 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Angioedema/Angioedema-like or Colorectal Events (Core : Active Treatment Phase)</title>
          <description>AEs of special interest were reported according to a post-marketing commitment to Health Authorities and included angioedema/angioedema-like events and colorectal events/ procedures</description>
          <population>Safety Set (SAF) - All patients who received at least one dose of trial medication. Patients were analyzed according to the treatment they received.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4272"/>
                <count group_id="O2" value="4285"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Angioedema / angioedema-like events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colorectal events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) to Month 6 and to Last Measurement (Core : Active Treatment Phase)</title>
        <description>Baseline is the geometric mean of last 3 measurements before visit 3, Post-baseline value is the geometric mean of last 3 measurements during each visit.
Change from Baseline = Post - Baseline.</description>
        <time_frame>Baseline, Month 6 , last measurement (maximum at 50 months)</time_frame>
        <population>Full Analysis Set (FAS) - All patients randomized except mis-randomized patients who did not receive study drug. Last observation carried forward (LOCF) computation technique was used for month 6 data. At each visit, only patients with values at both baseline and this time point are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>In Core (Double Blind) phase, Aliskiren 150 mg once daily (o.d.) for 4 weeks; then patient was uptitrated to 300 mg o.d. at Visit 5/Week 4 (or 150 mg o.d. if patient could not tolerate target dose of study drug). Visits took place at 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>In Core (Double Blind) Phase, Placebo to match aliskiren 150 mg once daily (o.d.) for 4 weeks; from Visit 5/Week 4 placebo to match aliskiren 300 mg o.d. (or placebo to match aliskiren 150 mg if patient could not tolerate target dose of study drug). Visits took place 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) to Month 6 and to Last Measurement (Core : Active Treatment Phase)</title>
          <description>Baseline is the geometric mean of last 3 measurements before visit 3, Post-baseline value is the geometric mean of last 3 measurements during each visit.
Change from Baseline = Post - Baseline.</description>
          <population>Full Analysis Set (FAS) - All patients randomized except mis-randomized patients who did not receive study drug. Last observation carried forward (LOCF) computation technique was used for month 6 data. At each visit, only patients with values at both baseline and this time point are included.</population>
          <units>mg/mmol</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4274"/>
                <count group_id="O2" value="4287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to Month 6 (n= 4021, 4040)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.841" lower_limit="0.820" upper_limit="0.862"/>
                    <measurement group_id="O2" value="0.945" lower_limit="0.922" upper_limit="0.968"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to Last Measurement (n= 4045, 4080)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.872" lower_limit="0.842" upper_limit="0.903"/>
                    <measurement group_id="O2" value="1.043" lower_limit="1.009" upper_limit="1.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Changes in Estimated Glomerular Filtration Rate (eGFR) From Baseline to Month 3 and Month 6 (Core : Active Treatment Phase)</title>
        <description>The eGFR calculation was based on the Abbreviated Modification of Diet in Renal Disease (MDRD) Study Equation. Using this method, the applicable MDRD formula to calculate eGFR was as follows:
Estimated GFR (mL/min/1.73 m^2) = 175 x (serum creatinine in mg/dL) -1.154 x (Age in years) -0.203 x (0.742 if female) x (1.210 if Black)
Mean changes in eGFR from baseline to month 3 and month 6 were included for analysis. The LS Mean and Standard Error were based on an ANCOVA repeated-measure model with treatment, visit, treatment-by-visit and baseline eGFR as effect terms.</description>
        <time_frame>Baseline to Month 3 and Month 6</time_frame>
        <population>Full Analysis Set (FAS) - All patients randomized except mis-randomized patients who did not receive study drug. At each visit (baseline, Month 3 and Month 6) , only patients with values at both baseline and post-baseline time point are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>In Core (Double Blind) phase, Aliskiren 150 mg once daily (o.d.) for 4 weeks; then patient was uptitrated to 300 mg o.d. at Visit 5/Week 4 (or 150 mg o.d. if patient could not tolerate target dose of study drug). Visits took place at 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>In Core (Double Blind) Phase, Placebo to match aliskiren 150 mg once daily (o.d.) for 4 weeks; from Visit 5/Week 4 placebo to match aliskiren 300 mg o.d. (or placebo to match aliskiren 150 mg if patient could not tolerate target dose of study drug). Visits took place 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Changes in Estimated Glomerular Filtration Rate (eGFR) From Baseline to Month 3 and Month 6 (Core : Active Treatment Phase)</title>
          <description>The eGFR calculation was based on the Abbreviated Modification of Diet in Renal Disease (MDRD) Study Equation. Using this method, the applicable MDRD formula to calculate eGFR was as follows:
Estimated GFR (mL/min/1.73 m^2) = 175 x (serum creatinine in mg/dL) -1.154 x (Age in years) -0.203 x (0.742 if female) x (1.210 if Black)
Mean changes in eGFR from baseline to month 3 and month 6 were included for analysis. The LS Mean and Standard Error were based on an ANCOVA repeated-measure model with treatment, visit, treatment-by-visit and baseline eGFR as effect terms.</description>
          <population>Full Analysis Set (FAS) - All patients randomized except mis-randomized patients who did not receive study drug. At each visit (baseline, Month 3 and Month 6) , only patients with values at both baseline and post-baseline time point are included.</population>
          <units>mL/min/1.73 m^2</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4113"/>
                <count group_id="O2" value="4130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.048" spread="0.15"/>
                    <measurement group_id="O2" value="-0.825" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Angioedema/Angioedema-like Events or Colorectal Events (Extension Phase)</title>
        <description>AEs of special interest were reported according to a post-marketing commitment to Health Authorities and included angioedema/angioedema-like events and colorectal events/ procedures.</description>
        <time_frame>From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)</time_frame>
        <population>Extension-phase Analysis Set (EAS) – All patients who had at least one scheduled or unscheduled visit or who died post cut-off date 20-Dec-2011/end of treatment (EOT).</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Angioedema/Angioedema-like Events or Colorectal Events (Extension Phase)</title>
          <description>AEs of special interest were reported according to a post-marketing commitment to Health Authorities and included angioedema/angioedema-like events and colorectal events/ procedures.</description>
          <population>Extension-phase Analysis Set (EAS) – All patients who had at least one scheduled or unscheduled visit or who died post cut-off date 20-Dec-2011/end of treatment (EOT).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3773"/>
                <count group_id="O2" value="3817"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Angioedema/ Angioedema-like event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colorectal events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Core-phase: Aliskiren</title>
          <description>In Core (Double Blind) phase, Aliskiren 150 mg once daily (o.d.) for 4 weeks; then patient was uptitrated to 300 mg o.d. at Visit 5/Week 4 (or 150 mg o.d. if patient could not tolerate target dose of study drug). Visits took place at 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.</description>
        </group>
        <group group_id="E2">
          <title>Core-phase: Placebo</title>
          <description>In Core (Double Blind) Phase, Placebo to match aliskiren 150 mg once daily (o.d.) for 4 weeks; from Visit 5/Week 4 placebo to match aliskiren 300 mg o.d. (or placebo to match aliskiren 150 mg if patient could not tolerate target dose of study drug). Visits took place 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until final closure of the study.</description>
        </group>
        <group group_id="E3">
          <title>Extension-phase: Aliskiren</title>
          <description>With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
        </group>
        <group group_id="E4">
          <title>Extension-phase: Placebo</title>
          <description>With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1988" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1893" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="704" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="682" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Anaemia haemolytic autoimmune</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Anaemia macrocytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Anaemia of chronic disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Anaemia vitamin B12 deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Aplastic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy mediastinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Nephrogenic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Spontaneous haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cardiac amyloidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cardiac asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="173" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="173" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cardiac fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diastolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Dilatation ventricular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypertensive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Mitral valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Nodal arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Nodal rhythm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pericarditis constrictive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Postinfarction angina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Silent myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Sinus arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Supraventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Tachycardia paroxysmal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Trifascicular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Arnold-Chiari malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Congenital arterial malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Familial hypocalciuric hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Haemoglobinopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypertrophic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Rathke's cleft cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Sickle cell anaemia with crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cushing's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypoparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Inappropriate antidiuretic hormone secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Primary hyperaldosteronism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Amaurosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Angle closure glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cataract diabetic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cataract nuclear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cataract subcapsular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Corneal degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cystoid macular oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Detachment of macular retinal pigment epithelium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diabetic eye disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ectropion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Iris adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lenticular opacities</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Macular fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ocular hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Optic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pterygium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Retinopathy proliferative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Vitreous adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Abdominal strangulated hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Colitis microscopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diabetic enteropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diabetic gastroenteropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diabetic gastroparesis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diverticulitis intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Duodenal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Enterocolitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Functional gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastric mucosa erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastritis atrophic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastrointestinal dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hypomotility</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hernial eventration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Intestinal angina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Intestinal infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Intestinal mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Intestinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ischaemic pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Large intestinal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lip oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Mesenteric occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Oesophageal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Palatal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pancreatic mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pancreatolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Peptic ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Peptic ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Peritoneal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pneumatosis intestinalis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Portal hypertensive gastropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Retroperitoneal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Salivary gland calculus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Sciatic hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Small intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Stress ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Swollen tongue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Thrombosis mesenteric vessel</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Device battery issue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Device electrical finding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Device lead issue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Drug intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Fat tissue increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>General symptom</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Granuloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Localised oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Oedema due to cardiac disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pelvic mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Perforated ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Biliary cirrhosis primary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Biliary cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Dilatation intrahepatic duct acquired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hepatic artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hepatic congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hepatitis cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hepatorenal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Contrast media allergy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Iodine allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Secondary immunodeficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>American trypanosomiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Appendiceal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Biliary abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bone abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cellulitis of male external genital organ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Chronic hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cystitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cystitis klebsiella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Eczema infected</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Emphysematous pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Endocarditis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Endotoxic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Enteritis necroticans</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Enterobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Epiglottitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gallbladder abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gas gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastrointestinal viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>HIV infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Infected bites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Infected bunion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Infected fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Infective spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Keratitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Listeria sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lymph node tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Mastoid abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Mediastinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Myelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Myiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Nosocomial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Oropharyngeal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Osteomyelitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Parvovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pericoronitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Perihepatic abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Peritoneal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pneumonia necrotising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pneumonia pseudomonas aeruginosa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Post procedural cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Post procedural sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Prostate infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Proteus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Purulent discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pyonephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Q fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Renal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Respiratory moniliasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Schistosomiasis liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Scrotal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Septic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Sinusitis fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Splenic abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Tongue abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Tuberculous pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ureteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Urinary tract infection pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Viral diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Viral pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Abdominal wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Accidental exposure to product</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Arterial injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Arterial restenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bone contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Burns third degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Carbon monoxide poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Fat embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Foreign body aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Foreign body in eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Haemodialysis complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Heat stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Incision site complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Incision site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Incision site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Peritoneal dialysis complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Post laminectomy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Post procedural diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Post procedural myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Post-traumatic neck syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Postoperative fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Postoperative hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Postoperative respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Postpericardiotomy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Scratch</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Shunt occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Shunt stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Skin injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Spinal column injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Spinal cord injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Spinal cord injury cervical</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Suture rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Synovial rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Traumatic haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Traumatic lung injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Traumatic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Traumatic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Wound haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Anticoagulation drug level above therapeutic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Blood creatine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Blood glucose abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Brain natriuretic peptide increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Electrocardiogram ambulatory abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>HIV test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Occult blood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Occult blood positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Prothrombin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Red blood cell sedimentation rate increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Respiratory rate increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Urinary sediment present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diabetes with hyperosmolarity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diabetic complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hyperglycaemic hyperosmolar nonketotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hyperosmolar state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hyperphosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hyperproteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypervolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia unawareness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypovitaminosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Insulin resistance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Metabolic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Metabolic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Shock hypoglycaemic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Sodium retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Arthritis reactive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bone cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bone formation increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Fracture malunion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Fracture nonunion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gouty tophus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Inguinal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Knee deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Muscle atrophy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Muscle necrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Muscle rigidity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Myalgia intercostal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Myofascial pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Myopathy toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Neck mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Neuropathic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Osteolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Sjogren's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Tendon pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Abdominal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Adrenal adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Adrenal gland cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Adrenal gland cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Adrenal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Anal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Angiomyolipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Astrocytoma malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Benign laryngeal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Benign neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Benign pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bladder papilloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bone neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Brain cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Breast adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour of the duodenum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cerebellar tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Craniopharyngioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ear neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Endocrine neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Epithelioid mesothelioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Fibrosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gallbladder adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastric cancer stage IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastric neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tract adenoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Glioblastoma multiforme</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Glottis carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Intestinal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Invasive lobular breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Kaposi's sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Keratoacanthoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Large intestine benign neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Laryngeal papilloma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lip neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage I</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Malignant ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of renal pelvis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Malignant peritoneal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Melanoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Metastases to abdominal cavity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Metastases to peritoneum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Metastatic carcinoid tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Metastatic gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Myxofibrosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Neoplasm prostate</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Neoplasm skin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Neuroendocrine tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Neurofibroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Neuroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer stage IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Oesophageal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Osteochondroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ovarian neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Paraneoplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pelvic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Peritoneal carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Plasmacytoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pleural mesothelioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Rectal cancer stage IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Rectal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Renal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Salivary gland adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Small intestine adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Soft tissue cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Splenic neoplasm malignancy unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the cervix</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the tongue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Testis cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Thyroid adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Tumour ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ureteric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Uterine neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Vocal cord neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Apallic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Autonomic nervous system imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Autonomic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Basal ganglia infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Basilar artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Brain hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Brain stem haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Brain stem stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Carotid sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cerebellar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cerebral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cerebral thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cervical myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Complex partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Complicated migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Demyelination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diabetic autonomic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diabetic coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diabetic hyperosmolar coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Epidural lipomatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hemianopia homonymous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic coma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lateral medullary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Motor dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Motor neurone disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Movement disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Myelitis transverse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Neuroglycopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Normal pressure hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Occipital neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Peripheral sensorimotor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Peroneal nerve palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Phantom pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Posterior reversible encephalopathy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Simple partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Spinal claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Spinal cord haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Spinal cord oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Subdural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Subdural hygroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Thalamic infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Thalamus haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Thoracic outlet syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Thrombotic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ulnar neuritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Uraemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Vascular encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Vocal cord paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute stress disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Anger</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Echopraxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Mental disorder due to a general medical condition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Mood disorder due to a general medical condition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Post-traumatic stress disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Psychogenic pain disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Psychotic disorder due to a general medical condition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Social avoidant behaviour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Transient psychosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Albuminuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bladder cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bladder spasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bladder stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diabetic end stage renal disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis membranous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis rapidly progressive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Glycosuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Henoch-Schonlein purpura nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hydroureter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Intercapillary glomerulosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Micturition disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Neurogenic bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Renal amyloidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Renal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Renal hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ureteral polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Urethral obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Urinary bladder haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Urinary bladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Urine abnormality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Vesicoureteric reflux</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired phimosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Penile haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Prostatic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Prostatic obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Scrotal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Spermatocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Urogenital prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Vaginal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Vulval oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Allergic bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Alveolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Asthma late onset</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bronchopneumopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Dyspnoea at rest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Dyspnoea paroxysmal nocturnal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Eosinophilic pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Nasal turbinate hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Orthopnoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pharyngeal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pulmonary necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Restrictive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Rhinitis hypertrophic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Stridor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Thoracic haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Upper airway resistance syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Vocal cord cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diabetic dermopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diabetic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Dry gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Henoch-Schonlein purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Leukocytoclastic vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pustular psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Rash vesicular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Stasis dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Activities of daily living impaired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Drug abuser</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Aortic arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Aortic rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Arterial disorder</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Arterial insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis Moenckeberg-type</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Blood pressure inadequately controlled</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diabetic macroangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diabetic vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Distributive shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Embolism arterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Essential hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Femoral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Femoral artery embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Haemodynamic instability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Iliac artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Labile hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Leriche syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Neovascularisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Peripheral circulatory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Poor peripheral circulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Subclavian artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Subclavian steal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Varicophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Varicose ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Vascular stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Venous insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3205" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="3069" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="995" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="1023" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="270" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="270" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="94" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="76" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="202" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="241" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="405" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="305" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="655" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="670" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="130" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="112" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="217" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="211" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="61" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="398" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="369" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="83" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="89" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="214" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="215" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="58" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="286" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="243" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="88" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1650" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="1229" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="270" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="252" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="334" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="297" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="98" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="87" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="295" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="299" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="51" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="360" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="344" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="292" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="311" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="314" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="305" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="188" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="219" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="352" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="321" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="87" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="256" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="280" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="380" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="410" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="121" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="105" subjects_at_risk="3817"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="496" subjects_at_risk="4272"/>
                <counts group_id="E2" subjects_affected="321" subjects_at_risk="4285"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="3773"/>
                <counts group_id="E4" subjects_affected="58" subjects_at_risk="3817"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>trialandresults.registries@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

